ascopubs.org24d
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Casdatifan (Cas) monotherapy in ...
The Globe and Mail24d
Advanced Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Advanced Melanoma Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape. It covers the ...
ascopubs.org23d
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).
Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.
UroToday8d
ASCO GU 2025: KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Dr. Kathryn E. Beckermann presented KEYMAKER-U03 Substudy 03B of pembrolizumab plus targeted therapy combination for advanced clear cell renal cell carcinoma (ccRCC). Despite high response rates, ...